The following paragraph is taken of from Feuerstein's blog posted this morning. There is a critical typo, so I post here.
"Pharmasset has already partnered development of R7128 with Swiss drug firm Roche. So far, R7128 looks a lot better than Roche's internal hepatitis C candidate <<R6126>>. That drug, while showing impressive efficacy at the meeting, also has some gnarly side effects, including high rates of neutropenia (low white-blood-cell counts that can lead to infection) and thrombocytopenia (low platelet counts that increase the risk of bleeding)."
R6126 highlighted above cannot be found in literature or by googling. This must be R1626 misstyped. This drug will go down the drain just as NM283 and HCV796 have done, and it will take a miracle for R7128 to pass the safety test.
Moreover, this class of drugs does not have the synergy with IFN although the drug effects may be additive. Protease inhibitors are unique in that it foils the sabotage attempt on immunity by HCV protease without which HCV cannot survive. This immune evasion by HCV using its protease has been validated over and over by researchers in the past two years.
I totally agree with you. Polymerese compoundas may work short term, but long term they have extremely bad side effect. Look at IDIX's polymerese. It work well in phase I but once patients took it for a longer period of time in phase II hell broke loose. Finally FDR put a stop in any further experimentation of that crap. I lost a decent amount of money on that POS which was first recommended on this board by Dew Dilligence. He however, is an honorable guy -- just wrong about polymerese effectiveness.